Jasmin Barman‐Aksözen

Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice

Debby Wensink, Margreet A. E. M. Wagenmakers, Jasmin Barman‐Aksözen et al. · JAMA Dermatology · 2020 · 49 citations · Full text

In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability

Jasmin Barman‐Aksözen, Elisabeth I. Minder, Carina Schubiger et al. · Blood Cells Molecules and Diseases · 2014 · 48 citations

Biology, Alas2 Expression, Biosynthesis +14

Iron availability modulates aberrant splicing of ferrochelatase through the iron- and 2-oxoglutarate dependent dioxygenase Jmjd6 and U2AF65

Jasmin Barman‐Aksözen, Chantal Béguin, Afzal M. Dogar et al. · Blood Cells Molecules and Diseases · 2013 · 38 citations

Iron Availability Modulates, Biochemistry, Heme Homeostasis +9

Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide – a three years observational study

Jasmin Barman‐Aksözen, Michèle Nydegger, Xiaoye Schneider‐Yin et al. · Orphanet Journal of Rare Diseases · 2020 · 29 citations · Full text

Disturbed iron metabolism in erythropoietic protoporphyria and association of GDF15 and gender with disease severity

Jasmin Barman‐Aksözen, Domenico Girelli, Caterina Aurizi et al. · Journal of Inherited Metabolic Disease · 2017 · 28 citations